NCT06335979View on ClinicalTrials.gov

An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).

PHASE1RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

October 8, 2024

Primary Completion Date

July 9, 2027

Study Completion Date

July 9, 2027

Conditions
Systemic Lupus Erythematosus, SLE
Interventions
DRUG

PIT565

In each cohort, there will be 3 sentinel participants. Additional participants might be added depending on safety and observed biological activity.

Trial Locations (10)

1612

WITHDRAWN

Novartis Investigative Site, Sofia

3010

RECRUITING

Novartis Investigative Site, Bern

9007

RECRUITING

Novartis Investigative Site, Sankt Gallen

10117

RECRUITING

Novartis Investigative Site, Berlin

15706

RECRUITING

Novartis Investigative Site, Santiago de Compostela

55131

RECRUITING

Novartis Investigative Site, Mainz

100191

RECRUITING

Novartis Investigative Site, Beijing

100730

RECRUITING

Novartis Investigative Site, Beijing

2333 CL

RECRUITING

Novartis Investigative Site, Leiden

08035

RECRUITING

Novartis Investigative Site, Barcelona

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY